Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication

• Main Authors: Genichiro Tsuji (Author), Shogo Nakajima (Author), Koichi Watashi (Author), Shiho Torii (Author), Rigel Suzuki (Author), Takasuke Fukuhara (Author), Nobumichi Ohoka (Author), Takao Inoue (Author), Yosuke Demizu (Author)
• Formato: Livro
• Publicado em: Elsevier, 2022-07-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we...